Moreover, extra caution should be taken to avoid unwanted deleterious side effects when using TRP channel blockers to treat CHS in ACD because the same TRP channel, for instance, TRPV1, might play distinct roles in skin inflammation and itch. Here, TRPV1 is linked to granular corneal dystrophy type II.